

RESAR REtroperitoneal SArcoma Registry

ClinicalTrials.gov Identifier: **NCT03838718**

Investigators' Meeting

Activation Track as of January 2019

- Active sites: 29
 - Enrolling: 27
- Submitted to IRB: 4
- Planning to submit: 14
- Potentially involved centers: 47




Partecipating sites distribution



- Europe 23
- North America 16
- Central America 1
- Asia 6
- Australia 1




Enrolling Sites




		Institution	City	State	Activation Status
1		Peter MacCallum Cancer Center	Melbourne	Australia	Recruiting
2		The Ottawa Hospital	Ottawa	Canada	Recruiting
3		Mount Sinai / Princess Margaret	Toronto	Canada	Recruiting
4		Institut Curie	Paris	France	Recruiting
5		Institut Bergonié	Bordeaux	France	Recruiting
6		Ludwig Maximilian University	Munich	Germany	Recruiting
7		Campus Biomedico	Roma	Italy	Recruiting
8		Fondazione IRCCS Istituto Nazionale dei Tumori	Milano	Italy	Recruiting
9		Veneto Institute of Oncology	Padova	Italy	Recruiting
10	FIRST RECRUITED IN 2018	Ospedale Borgo Roma	Verona	Italy	Recruiting
11	FIRST RECRUITED IN 2018	European Institute of Oncology	Milano	Italy	Recruiting
12		Candiolo Cancer Institute	Candiolo	Italy	Recruiting
13		Maria Sklodowska-Curie Memorial Cancer Center	Warsaw	Poland	Recruiting
14		Institute of Oncology Ljubljana	Ljubljana	Slovenia	Recruiting
15		Samsung Medical Center	Seoul	South Korea	Recruiting
16		Hospital Clinico Universitario "Virgen de la Arrixaca"	Murcia	Spain	Recruiting
17	FIRST RECRUITED IN 2019	Hospital Sant Pau	Barcelona	Spain	Recruiting
18		Netherlands Cancer Institute	Amsterdam	The Netherlands	Recruiting
19		Royal Marsden Hospital	London	UK	Recruiting
20		Queen Elizabeth Hospital Birmingham	Birmingham	UK	Recruiting
21		University of Southern California (USC)	Los Angeles	USA	Recruiting
22		Mayo Clinic	Jacksonville	USA	Recruiting
23		Moffitt Cancer Center	Tampa	USA	Recruiting
24		Winship Cancer Institute, Emory University	Atlanta	USA	Recruiting
25		Brigham and Women's Hospital/Dana-Farber Cancer Institute	Boston	USA	Recruiting
26	FIRST RECRUITED IN 2018	Roswell Park Comprehensive Cancer Center	Buffalo	USA	Recruiting
27		The Ohio State University	Columbus	USA	Recruiting
28		Humanitas Cancer Center	Rozzano	Italy	Approved, ready to recruit
29		Maisonneuve-Rosemont Hospital / University of Montreal	Montreal	Canada	Approved, ready to recruit


	Institution	City	State	Activation Status
1	Peking University International Hospital	Beijing	China	Submitted to IRB, pending for decision
2	Città della Salute e della Scienza	Turin	Italy	Submitted to IRB, pending for decision
3	Leiden University Medical Center	Leiden	The Netherlands	Submitted to IRB, pending for decision
4	Mary Bird Perkins Cancer Center	Baton Rouge	USA	Submitted to IRB, pending for decision
1	University of Athens	Athens	Greece	Planning to submit to IRB
2	The Chinese University of Hong Kong / Prince of Wales Hospital	Hong Kong	Hong Kong	Planning to submit to IRB
3	Christian Medical College	Vellore	India	Planning to submit to IRB
4	Tallaght Univesity Hospital	Dublin	Ireland	Planning to submit to IRB
5	Tel-Aviv Sourasky Medical Center	Tel-Aviv	Israel	Planning to submit to IRB
6	Ospedale Garibaldi	Catania	Italy	Planning to submit to IRB
7	National Cancer Center Hospital	Tokyo	Japan	Planning to submit to IRB
8	Instituto National de Cancerologia	Mexico City	Mexico	Planning to submit to IRB
9	Hospital Gregorio Maranon	Madrid	Spain	Planning to submit to IRB
10	UC Davis	Sacramento	USA	Planning to submit to IRB
11	Fox Chase Cancer Center	Philadelphia	USA	Planning to submit to IRB
12	Johns Hopkins University	Baltimore	USA	Planning to submit to IRB
13	Massachusetts General Hospital	Boston	USA	Planning to submit to IRB
14	University of Washington	Seattle	USA	Planning to submit to IRB

Enrollment as of January 2019



Projection according to accrual of last 4 months





- Amsterdam
- Atlanta
- Barcelona
- Birmingham
- Bordeaux
- Boston
- Buffalo
- Candiolo
- Curie
- INT
- Jacksonville
- Ljubljana
- Los Angeles
- Melbourne
- IEO
- Munich
- Murcia
- Ohio State Univ
- Ottawa
- Padova
- RMH
- Roma
- Seoul
- Tampa
- Toronto
- Verona
- Warsaw

Funding

- Approval for Institutional grant is presently ongoing at INT Milan
- This would allow data centralization and data monitoring for the registry for 5 years
- IT platform for semi-automatic uploading will be provided
- No other funding option envisaged to date
- **ACTION:** as proposed during last TARPSWG semiannual meeting, agree to centralize data in Milan?



Expanding registry to
“persistent primary RPS”
After uncomplete surgery

- Proposed during TARPSWG meeting in Nov 2018
- Expanded dataset to be approved



“Previous Incomplete Surgery”

TARPSWG Registry
Progetto TMS - Vers. 3.0
Data: sabato 23 marzo 2019
User: Marco

Patient ID: 3732201 | Surname: Bonardi | Given Name(s): Adelaide | Sex: F | Birth date: 09/06/1939 | Age: 79

Street Address: Via Cesare Battisti 16 Cornaredo MI | ZIP Code: 20010 | Phone numbers: 0293569391 | 3282871149

Solitary fibrous tumour G1 Right Retroperitoneum

Demographics | Imaging | Surgical Treatment | Pathology | Radiation Oncology | Medical Oncology | Recurrence | Vital Status

Preoperative medical conditions | Anticipated concomitant resection | Surgical procedure | Resected organs at primary surgery | Postoperative events

Height (cm): 150
Weight (kg): 53

CO-MORBIDITY REVISOR

Hypertension ☐ No ☒ Yes
Diabetes mellitus ☒ No ☐ Yes
COPD ☒ No ☐ Yes
Coronary artery disease ☐ No ☒ Yes
Chronic renal disease ☐ No ☒ Yes
If other, specify (50 max.):

Last blood tests before surgery REVISOR

Hemoglobin: 10.7 g/dL
WBC: 3.56 1000/uL
Neutrophils (%): 68
Lymphocytes (%): 17.5
Monocytes (%): 9
CRP (mg/L): 3
Creatinine: 1.13 mg/dL
Albumin (g/dL): 3.9
Platelet count (10⁹/μL): 220



Category	Options	Category	Options
1) Date of PIS		8) Surgical approach	Laparotomy
2) Biopsy before PIS	Yes/No		Laparoscopy
3) If not, RPS suspected?	Yes/No		Robotic
4) Imaging before PIS	Yes/No		Retroperitoneal approach
5) Hospital of PIS	Academic		Inguinotomy
	Cancer Center		Other
	Community Hospital	9) Final surgical report by previous surgeon	Complete resection
	Private Clinic		Incomplete resection
	Other	10) Type of procedure	Simple partial resection
6) Surgeon of PIS	Surgical Oncologist		Piecemeal partial resection
	General Surgeron		Partial resection + enbloc visceral resection
	Urologist		Partial resection + visceral resection not enbloc
	Gynecologist	11) Resected organs	Complete list
	Other	12) Size of primary at time of PIS	Maximum diameter, even in case of piecemeal
7) Type of procedure	Planned	13) Postsurgical complications	No
	Emergency		Bleeding
	Occasional finding during different procedure		Leak
	Misdiagnosed for different entity (e.g. inguinal hernia)		Other
			NA
		14) Date of first available imaging after PIS	

“Second malignancies”

TARPSWG Registry
Progetto TMS - Vers. 3.0
Data: sabato 23 marzo 2019
User: Marco

Patient ID: 3732201 | Surname: Bonardi | Given Name(s): Adelaide | Sex: F | Birth date: 09/06/1939 | Age: 79

Street Address: Via Cesare Battisti 16 Cornaredo MI | ZIP Code: 20010 | Phone numbers: 0293569391 | 3282871149

Solitary fibrous tumour G1 Right Retroperitoneum

Demographics | Imaging | Surgical Treatment | Pathology | Radiation Oncology | Medical Oncology | Recurrence | Vital Status

Preoperative medical conditions | Anticipated concomitant resection | Surgical procedure | Resected organs at primary surgery | Postoperative events

Height (cm): 150 | Weight (kg): 53

CO-MORBIDITY **REVISOR**

Hypertension: ☐ No ☒ Yes
Diabetes mellitus: ☒ No ☐ Yes
COPD: ☒ No ☐ Yes

Last blood tests before surgery **REVISOR**

Hemoglobin: 10.7 g/dL
WBC: 3.56 1000/uL
Neutrophils (%): 68

ANTICANCER RESEARCH 38: 3535-3542 (2018)
doi:10.21873/anticancer.12625

Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma

ERIC JUNG¹, MARCO FIORE², ALESSANDRO GRONCHI², VALERIE GRIGNOL³, RAPHAEL E. POLLOCK³, SUSAN S. CHONG¹, SHEFALI CHOPRA⁴, ANN S. HAMILTON⁵ and WILLIAM W. TSENG¹

- 8.3% with WD/DD liposarcoma had a second primary cancer identified within 2 years of liposarcoma diagnosis



Category	Options	Category	Options
1) Other malignancy	Yes/No	3) Time	Previous
2) Type	Breast		Synchronous
	Colon		Metacronous
	Lung	4) Year of diagnosis	
	Pancreas	5) Stage	
	Liver		
	Kidney		
	Prostate		
	Ovary		
	Uterus		
	Brain		
	Melanoma		
	GIST		
	Soft Tissue Sarcoma		
	Other		


Study TARPSWG 1901

Title of Project:

Prediction of morbidity following surgery for primary retroperitoneal sarcomas using a surgical complexity score – an analysis within the RETroperitoneal SARcoma Registry (RESAR)

Will you join the data merge for the "Complexity Score project"?

29 response



24 centers opt in for TARPSWG 1901
Enrolled patients Jan2017-Jan2019: **816**




Study TARPSWG 1901

Title of Project:

Prediction of morbidity following surgery for primary retroperitoneal sarcomas using a surgical complexity score – an analysis within the REtroperitoneal SARcoma Registry (RESAR)

Do you need to sign a data transfer agreement for data merge?

29 risposte



For data transfer agreement:

- A contract letter will be provided from INT to be sign
- Please provide PI and Legal Representative email address to marco.fiore@istitutotumori.mi.it
- ***Those centers that already communicate data, will receive the contract in next weeks***



Study TARPSWG 1901

Title of Project:

Prediction of morbidity following surgery for primary retroperitoneal sarcomas using a surgical complexity score – an analysis within the REtroperitoneal SARcoma Registry (RESAR)

Proposed timeline:

- Mid April: close opt in
- Mid May: finalize DTA and centralization of data
- End June: data cleaning and data query to participating centers
- September: final statistical report
- Abstract to SSO 2020?

